A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351
Phase of Trial: Phase IV
Latest Information Update: 04 Sep 2015
Price : $35 *
At a glance
- Drugs Bapineuzumab (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms RAPID
- Sponsors JANSSEN Alzheimer Immunotherapy
- 24 Aug 2012 Planned end date (Sep 2012) added as reported by ClinicalTrials.gov.
- 24 Aug 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Aug 2012 New trial record